Pharmacological agents, such as bezafibrate, that activate peroxisome proliferator-activated receptors (PPARs) and PPAR γ coactivator-1α (PGC-1α) pathways have been shown to improve mitochondrial function and energy metabolism. The mitochondrial DNA (mtDNA) mutator mouse is a mouse model of aging that harbors a proofreading-deficient mtDNA polymerase γ. These mice develop many features of premature aging including hair loss, anemia, osteoporosis, sarcopenia and decreased lifespan. They also have increased mtDNA mutations and marked mitochondrial dysfunction. We found that mutator mice treated with bezafibrate for 8-months had delayed hair loss and improved skin and spleen aging-like phenotypes. Although we observed an increase in markers of fatty acid oxidation in these tissues, we did not detect a generalized increase in mitochondrial markers. On the other hand, there were no improvements in muscle function or lifespan of the mutator mouse, which we attributed to the rodent-specific hepatomegaly associated with fibrate treatment. These results showed that despite its secondary effects in rodent’s liver, bezafibrate was able to improve some of the aging phenotypes in the mutator mouse. Because the associated hepatomegaly is not observed in primates, long-term bezafibrate treatment in humans could have beneficial effects on tissues undergoing chronic bioenergetic-related degeneration.
References
[1]
Dillon LM, Rebelo AP, Moraes CT (2012) The role of PGC-1 coactivators in aging skeletal muscle and heart. IUBMB Life 64: 231–241.
[2]
Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, et al. (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417–423.
[3]
Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, et al. (2005) Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481–484.
[4]
Dillon LM, Williams SL, Hida A, Peacock JD, Prolla TA, et al. (2012) Increased mitochondrial biogenesis in muscle improves aging phenotypes in the mtDNA mutator mouse. Hum Mol Genet 21: 2288–2297.
[5]
Tenenbaum A, Motro M, Fisman EZ (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4: 14.
[6]
Wang YX (2010) PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 20: 124–137.
Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008) Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8: 249–256.
[9]
Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, et al. (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet 21: 1124–1137.
[10]
Yatsuga S, Suomalainen A (2011) Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet.
[11]
Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, et al. (2011) In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab 14: 80–90.
[12]
Oikarinen A (1994) Aging of the skin connective tissue: how to measure the biochemical and mechanical properties of aging dermis. Photodermatol Photoimmunol Photomed 10: 47–52.
[13]
Verrecchia F, Chu ML, Mauviel A (2001) Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276: 17058–17062.
[14]
Ham SA, Kim HJ, Kang ES, Eun SY, Kim GH, et al. (2010) PPARdelta promotes wound healing by up-regulating TGF-beta1-dependent or -independent expression of extracellular matrix proteins. J Cell Mol Med 14: 1747–1759.
[15]
Smaldone S, Olivieri J, Gusella GL, Moroncini G, Gabrielli A, et al. (2011) Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis Tissue Repair 4: 8.
[16]
Cesta MF (2006) Normal structure, function, and histology of the spleen. Toxicol Pathol 34: 455–465.
[17]
Harries MJ, Paus R (2009) Scarring alopecia and the PPAR-gamma connection. J Invest Dermatol 129: 1066–1070.
[18]
Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, et al. (2010) Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PLoS One 5: e11468.
[19]
De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG (2006) Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. Toxicol Sci 92: 578–586.
[20]
Djouadi F, Bastin J (2011) Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders. Cell Metab 14: 715–716; author reply 717.
[21]
Ahlqvist KJ, Hamalainen RH, Yatsuga S, Uutela M, Terzioglu M, et al. (2012) Somatic progenitor cell vulnerability to mitochondrial DNA mutagenesis underlies progeroid phenotypes in Polg mutator mice. Cell Metab 15: 100–109.
[22]
Cheung MC, Spalding PB, Gutierrez JC, Balkan W, Namias N, et al. (2009) Body surface area prediction in normal, hypermuscular, and obese mice. J Surg Res 153: 326–331.
[23]
Pickrell AM, Fukui H, Wang X, Pinto M, Moraes CT (2011) The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J Neurosci 31: 9895–9904.
